Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.
Company to Feature 17 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology
Hematology Presentations Include New Data from the Phase 3 and Continuation Trials Supporting.
-Record Net Product Sales of $544 Million in 2Q23, an Increase of 26% Over 2Q22, Contributing to Total Revenues of $604 Million in 2Q23-
-Strong PADCEV® Growth Driven By Combination First-Line.